Article Information
vol. 11 no. 489
- Received for publication November 17, 2017
- Resubmitted July 19, 2018
- Accepted for publication March 11, 2019
- .
Author Information
- Howard J. Seeherman1,*,
- Stephen P. Berasi2,
- Christopher T. Brown1,
- Robert X. Martinez3,
- Z. Sean Juo4,
- Scott Jelinsky3,
- Michael J. Cain3,
- Jaclyn Grode1,
- Kathleen E. Tumelty2,
- Marc Bohner5,
- Orly Grinberg6,
- Nadav Orr6,
- Oded Shoseyov6,
- Jeroen Eyckmans7,8,
- Christopher Chen7,8,
- Pablo R. Morales9,
- Christopher G. Wilson1,
- Eric J. Vanderploeg1 and
- John M. Wozney1
- 1Bioventus Surgical, Bioventus LLC, Boston, MA 02215, USA.
- 2Centers for Therapeutic Innovation, Pfizer Inc., Boston, MA 02115, USA.
- 3Department of Inflammation and Immunology, Pfizer Inc., Cambridge, MA 02139, USA.
- 4Biomedical Design, Pfizer Inc., Cambridge, MA 02139, USA.
- 5Robert Mathys Stiftung (RMS) Foundation, Bettlach 2544, Switzerland.
- 6CollPlant Ltd., Ness Ziona 74140, Israel.
- 7Biological Design Center and Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA.
- 8Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA 02115, USA.
- 9Mannheimer Foundation Inc., Homestead, FL 33034, USA.
- ↵*Corresponding author. Email: hseeherman{at}gmail.com